Liver Dysfunction Clinical Trial
Official title:
The Impact of Sevoflurane and Propofol Anesthesia on Hepatic Apoptosis Markers
Anesthesia may affect the function of vital organs. Liver is one of them. The investigator's hypothesis is that intravenous or inhalation anesthesia does not impair liver function as assessed by more elegant tests like markers indicating liver apoptosis. In the present randomized prospective trial female patients scheduled for mastectomy or thyroidectomy will receive inhalation or total intravenous anesthesia and markers for liver dysfunction will be determined.
Female patients undergoing mastectomy or thyroidectomy under sevoflurane or propofol
anesthesia will be recruited for the study. The type of anesthesia will be determined in a
random way using a computer generated table.
All patients will be preoxygenated for 3 minutes before induction of anesthesia. Patients
assigned to the sevoflurane group will receive an inhalation induction with sevoflurane via
a primed anesthetic circle system and anesthesia will be maintained with sevoflurane. In the
propofol group patients anaesthesia will be induced and maintained with propofol.
Blood samples for liver apoptotic markers will be collected before induction of anesthesia,
after skin closure as well as 24 and 48 hours postoperatively.
Blood samples will be centrifuged, stored at -80 degrees Celsius and analyzed for M30 and
M60 values with radioimmunoassay technique. Serum glutamic pyruvic transaminase (SGPT) and
serum glutamic oxaloacetic transaminase (SGOT) levels will also be determined.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02754219 -
Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction
|
Phase 1 | |
| Terminated |
NCT01079104 -
Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units
|
N/A | |
| Recruiting |
NCT00553553 -
Efficacy of Multimodal Opioid Therapy During Hepatic Resection Surgery
|
N/A | |
| Completed |
NCT03641872 -
A Validation Cohort for ACLF Diagnosis and Prognosis
|
||
| Completed |
NCT03371537 -
Study of Hemodynamic Conditions Measured During Hepatectomy
|
||
| Not yet recruiting |
NCT05559242 -
Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients
|
Phase 1 | |
| Recruiting |
NCT02473601 -
Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis
|
Phase 2 | |
| Completed |
NCT03155984 -
Optimizing HBV Management During Anti-CD20 Antibodies
|
||
| Recruiting |
NCT06126419 -
Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration
|
N/A | |
| Completed |
NCT03515980 -
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
|
Phase 1 | |
| Completed |
NCT01338714 -
The Effect of Compound Herbal Formula (RHD-1) on HBV Carrier With Abnormal Liver Function
|
Phase 3 | |
| Completed |
NCT02005744 -
A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function
|
Phase 1 | |
| Completed |
NCT01367522 -
Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function
|
Phase 1 | |
| Recruiting |
NCT03805139 -
Role of Ajwa Derived Polyphenols in Dyslipidaemias
|
N/A | |
| Enrolling by invitation |
NCT05082077 -
Global Utilization And Registry Database for Improved preservAtion of doNor Livers
|
||
| Completed |
NCT02949505 -
Impact of Exercise Therapy on Functional Capacity in Patients Listed for Liver Transplantation
|
N/A | |
| Completed |
NCT02991339 -
The Effects of Dexamethasone Administration on Jaundice Following Liver Resection
|
Phase 2/Phase 3 | |
| Completed |
NCT02992639 -
Weight Loss Effect on Circulating Liver Enzymes
|
N/A | |
| Recruiting |
NCT05793203 -
Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transplant Recipients
|
||
| Recruiting |
NCT03519074 -
Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction
|
Phase 2 |